Blog

Psygen stock

Press

Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction

Psygen Industries Ltd. (“Psygen“) and Larose Ventures Ltd. (“Larose Ventures” or the “Company“) are pleased to announce they have entered into a binding letter agreement (the “Letter Agreement“) dated March 23, 2021, to complete a business combination by way of a transaction that will constitute a reverse takeover of a wholly-owned subsidiary of the Company, being 1290442 B.C. Ltd. (“SpinCo“), by Psygen (the “Transaction“). The Transaction is conditional on, and will be effected after, the closing of the Company’s previously announced strategic reorganization, whereby the Company intends to spin out its interest in SpinCo, along with six other wholly-owned subsidiaries,…

Pharmather

Press

PharmaTher Advancing Research for Delivery of Ketamine

Newscope Capital Corporation, today announced that its wholly-owned subsidiary, PharmaTher Inc. has entered into a sponsored research agreement with The Queen’s University of Belfast for the development of a patented hydrogel-forming microneedle patch to deliver ketamine and the PharmaTher’s proprietary ketamine formulation, KETABET™”.

NeonMind

Press

NeonMind CEO Provides Update on Psilocybin Drug Development Research Plan

Quick Take: NeonMind CEO Rob Tessarolo provides an update on the company’s latest R&D initiatives, their 2021 roadmap, and near-future plans on developing synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder, and as an aid to weight loss and its maintenance. Over the next six weeks, NeonMind’s R&D group will finalize a fully integrated development program (IDP) NeonMind Biosciences Inc. (NEON), provides an update from CEO Rob Tessarolo on its research and development activities, as well as its plan to further develop two of its synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder…